Wall Street Zen Upgrades Harrow (NASDAQ:HROW) to "Hold"

Key Points

• Wall Street Zen upgraded Harrow from “sell” to “hold,” while overall analyst sentiment remains a “Moderate Buy” with a consensus price target of $69.43. Ratings are mixed, including BTIG’s “buy” and Zacks Research’s “strong sell.”
• Harrow shares rose 3% to open at $40.03, but the company reported a quarterly loss of $0.46 per share, missing estimates by $0.28, despite revenue of $70.66 million slightly exceeding expectations.
• Institutional investors own 72.76% of Harrow, and an insider recently purchased 1,000 shares. Potential growth from commercializing Tyrvaya contrasts with lowered earnings forecasts and ongoing concerns over profitability.

Harrow (NASDAQ:HROW - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.

HROW has been the topic of a number of other reports. Cantor Fitzgerald reduced their price target on shares of Harrow from $91.00 to $88.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 13th. BTIG Research reaffirmed a "buy" rating and set a $63.00 price objective on shares of Harrow in a research report on Tuesday. Zacks Research lowered shares of Harrow from a "hold" rating to a "strong sell" rating in a research note on Tuesday. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Harrow in a report on Monday, July 20th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $69.43.

Harrow Trading Up 3.0%

HROW opened at $40.03 on Friday. Harrow has a 12-month low of $28.54 and a 12-month high of $54.85. The company has a debt-to-equity ratio of 19.70, a current ratio of 2.24 and a quick ratio of 2.30. The stock has a market capitalization of $1.50 billion, a PE ratio of -40.03 and a beta of 0.28. The firm's fifty day moving average price is $40.94 and its 200 day moving average price is $39.88.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.28). The company had revenue of $70.66 million for the quarter, compared to the consensus estimate of $70.35 million. Harrow had a negative return on equity of 38.00% and a negative net margin of 13.51%. As a group, research analysts expect that Harrow will post 0.11 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Adrienne L. Graves bought 1,000 shares of the business's stock in a transaction on Monday, May 18th. The shares were bought at an average cost of $31.07 per share, for a total transaction of $31,070.00. Following the completion of the purchase, the director owned 1,000 shares of the company's stock, valued at $31,070. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.80% of the stock is owned by corporate insiders.

Institutional Trading of Harrow

A number of large investors have recently modified their holdings of the company. Larson Financial Group LLC lifted its position in Harrow by 13.1% in the 4th quarter. Larson Financial Group LLC now owns 2,446 shares of the company's stock valued at $120,000 after purchasing an additional 284 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Harrow by 2.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company's stock worth $505,000 after purchasing an additional 341 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Harrow by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company's stock worth $88,000 after purchasing an additional 369 shares during the last quarter. Captrust Financial Advisors increased its stake in shares of Harrow by 0.5% in the fourth quarter. Captrust Financial Advisors now owns 69,959 shares of the company's stock valued at $3,428,000 after purchasing an additional 376 shares during the period. Finally, Alliancebernstein L.P. increased its stake in shares of Harrow by 1.7% in the third quarter. Alliancebernstein L.P. now owns 29,520 shares of the company's stock valued at $1,422,000 after purchasing an additional 500 shares during the period. Institutional investors and hedge funds own 72.76% of the company's stock.

Key Harrow News

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: Harrow’s potential acquisition or commercialization of Viatris’ Tyrvaya could create a new growth opportunity if the company can expand the ophthalmic drug’s sales and reach. Viatris Is Selling Tyrvaya, but Could Harrow Turn It Into a Growth Engine?
• Positive Sentiment: A Seeking Alpha analysis characterized Harrow’s second-quarter turnaround as sufficient to support a cautious-buy view, offering a more constructive perspective on the company’s operating trajectory. Harrow: The Q2 Turnaround Is Enough for a Cautious Buy
• Positive Sentiment: BTIG Research reaffirmed its buy rating, signaling continued confidence in Harrow’s longer-term prospects. BTIG Research Reaffirms Buy Rating for Harrow
• Neutral Sentiment: HC Wainwright made a minor increase to its Q4 2027 EPS forecast, to $1.07 from $1.06, indicating limited improvement in one later-period estimate.
• Negative Sentiment: HC Wainwright significantly reduced its earnings forecasts: FY2026 moved to a loss of $0.57 per share from earnings of $0.15, FY2027 fell to $0.88 from $1.14, and Q3 2026 declined to $0.01 from $0.26. Estimates for Q1 and Q2 2027 were also lowered to losses of $0.63 and $0.12 per share, respectively. The revisions contrast with the current full-year consensus estimate of $0.30.
• Negative Sentiment: Zacks Research downgraded Harrow from “hold” to “strong sell,” adding to concerns about valuation and near-term profitability. Zacks.com
• Negative Sentiment: Recent coverage linked a prior gap lower in HROW shares to weak earnings, reinforcing investor concerns about the company’s ongoing losses and execution. Harrow Shares Gap Down Following Weak Earnings

About Harrow

Harrow Health, Inc NASDAQ: HROW is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source